Topics

Cara Therapeutics Announces Positive Topline Data from Mid-Stage Trial of Oral Korsuva in CKD Patients with Moderate-to-Severe Pruritus

10:09 EST 4 Dec 2019 | Speciality Pharma Journal

STAMFORD, Conn., Dec. 03, 2019 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus …

Original Article: Cara Therapeutics Announces Positive Topline Data from Mid-Stage Trial of Oral Korsuva in CKD Patients with Moderate-to-Severe Pruritus

NEXT ARTICLE

More From BioPortfolio on "Cara Therapeutics Announces Positive Topline Data from Mid-Stage Trial of Oral Korsuva in CKD Patients with Moderate-to-Severe Pruritus"

Quick Search

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...